Overall in Type 2 diabetes patients participating in the ONWARDS 1, 2, 3, and 5 trial, the effect of insulin icodec showed a significantly greater A1C reduction from baseline compared to insulin degludec, glargine U100, and glargine U300. The gene discussed is INS; the disease is type 2 diabetes mellitus.